These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20843837)

  • 1. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
    Jones MD; Liu JC; Barthel TK; Hussain S; Lovria E; Cheng D; Schoonmaker JA; Mulay S; Ayers DC; Bouxsein ML; Stein GS; Mukherjee S; Lian JB
    Clin Cancer Res; 2010 Oct; 16(20):4978-89. PubMed ID: 20843837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BU-32: a novel proteasome inhibitor for breast cancer.
    Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
    Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S
    Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
    Pratap J; Akech J; Wixted JJ; Szabo G; Hussain S; McGee-Lawrence ME; Li X; Bedard K; Dhillon RJ; van Wijnen AJ; Stein JL; Stein GS; Westendorf JJ; Lian JB
    Mol Cancer Ther; 2010 Dec; 9(12):3210-20. PubMed ID: 21159607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
    Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
    Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
    Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
    Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
    Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
    Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.
    Mao X; Pan X; Zhao S; Peng X; Cheng T; Zhang X
    Inflammation; 2012 Aug; 35(4):1378-91. PubMed ID: 22391745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
    Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
    Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
    Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
    J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.